Simplify Logo

Full-Time

Senior Manager

Digital Media and Communications

Posted on 6/27/2024

Arcellx

Arcellx

51-200 employees

Develops cell therapies for cancer, autoimmune diseases

Biotechnology
Healthcare

Compensation Overview

$120k - $160kAnnually

+ Bonus + Equity Grants + Relocation Assistance

Senior, Expert

San Carlos, CA, USA

Category
Content Strategy
Editing & Proofreading
Content & Writing
Copywriting
Required Skills
Communications
Journalism
Requirements
  • Bachelor's degree and at least 7+ years of related experience in journalism, digital media, public relations. Candidates with less experience will be considered at the manager level.
  • Knowledge of and experience with multiple online channels (YouTube, LinkedIn, Twitter, mobile devices), with a track record of growing and engaging online audiences.
  • Excellent writer and storyteller with the ability to craft thoughtful communications that will engage audiences (internally and externally) and create a unique POV for topics relevant to the executive team, company, and team members.
  • Strong attention to detail, project management, copy editing, understanding of multimedia and visual storytelling is a must.
  • Must be able to take feedback and quickly adapt content in a fast-paced environment.
  • Ability to translate complicated scientific concepts into engaging content.
Responsibilities
  • create and manage the editorial calendar and content for the Company’s internal and external communications/digital platforms, including curating content, incorporating the use of graphics, videos, infographics, and long-form articles, manage reviews, scheduling, distribution, and performance measurements across the internal and external platforms and channels.
  • Assist with writing and editing corporate communications materials, ensuring consistency in tone, style, and messaging.
  • Monitor opportunities for speaking engagements and award submissions and draft submissions.

Arcellx develops innovative cell therapies for cancer and autoimmune diseases, leveraging their novel D-Domain technology and transformative ddCAR and ARC-SparX platforms to enhance cell therapy.

Company Stage

N/A

Total Funding

$736M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

24%

1 year growth

33%

2 year growth

88%
Simplify Jobs

Simplify's Take

What believers are saying

  • The Phase 3 iMMagine-3 trial for anito-cel could significantly boost Arcellx's market position if successful.
  • Recent robust long-term responses from the Phase 1 expansion trial of anito-cel indicate promising efficacy and safety, potentially leading to FDA approval.
  • The $285M equity investment and upfront cash from Kite provide substantial financial backing for Arcellx's ongoing and future projects.

What critics are saying

  • The competitive landscape for CAR T therapies is intense, with established players like Abecma and Carvykti posing significant challenges.
  • Regulatory hurdles, such as the recent FDA partial hold, could delay product development and market entry.

What makes Arcellx unique

  • Arcellx's anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T therapy for multiple myeloma utilizing a novel D-Domain binder, setting it apart from existing treatments.
  • The company's strategic partnership with Kite, a Gilead Company, enhances its research capabilities and market reach, distinguishing it from smaller biotech firms.
  • Arcellx's focus on innovative immunotherapies for cancer and other incurable diseases positions it uniquely in the biotech landscape.
INACTIVE